Table 2.
Baseline and week 8 whole plasma lipids
| Placebo (N = 41) |
Anacetrapib alone (N = 95) |
Atorvastatin alone (N = 44) |
Anacetrapib + atorvastatin (N = 102) |
|||||
|---|---|---|---|---|---|---|---|---|
| Mean (SE) |
Mean (SE) |
Mean (SE) |
Mean (SE) |
|||||
| Parameter (mg/dL) | Baseline | Week 8 | Baseline | Week 8 | Baseline | Week 8 | Baseline | Week 8 |
| TC | 224 (5) | 228 (4) | 225 (3) | 234 (4) | 228 (4) | 161 (4) | 223 (3) | 179 (3) |
| LDL-C | 138 (4) | 141 (3) | 142 (2) | 84 (3) | 142 (3) | 81 (3) | 138 (2) | 45 (2) |
| HDL-C | 53 (2) | 55 (2) | 50 (1) | 118 (3) | 49 (2) | 52 (2) | 49 (1) | 109 (3) |
| TG | 145 (78) | 104 (40) | 147 (94) | 140 (84) | 162 (110) | 138 (79) | 152 (119) | 103 (62) |
| Non–HDL-C | 171 (4) | 173 (4) | 175 (3) | 115 (4) | 178 (4) | 109 (4) | 174 (3) | 70 (2) |
| Apo B | 140 (3) | 142 (3) | 141 (2) | 98 (2) | 146 (3) | 95 (3) | 141 (2) | 72 (2) |
| Apo AI | 172 (4) | 177 (5) | 169 (2) | 243 (3) | 166 (5) | 166 (4) | 164 (3) | 228 (4) |
| Lp(a) | 10 (19) | 12 (21) | 10 (25) | 5 (17) | 10 (23) | 10 (25) | 11 (28) | 5 (22) |
apoAI, apolipoprotein AI; apoB, apolipoprotein B; atorvastatin, atorvastatin 20 mg; CI, confidence interval; HDL, high-density lipoprotein; IQR, interquartile range; LDL, low-density lipoprotein; Lp(a), lipoprotein(a); SE, standard error; TC, total cholesterol; TG, triglyceride.
LDL-C estimated using Friedewald equation.
Anacetrapib, combined anacetrapib 150- and 300-mg treatment groups.